Skip to main content
OpenTrials
Completed

NCT Number: NCT00425100

A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients

To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pfizer Investigational Site, Brussels, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • OAB patients who present with OAB symptoms(≥8 micturitions and ≥3 urgency episodes per 24 h documented in the baseline bladder diary)
  • OAB patients dissatisfied with their prior therapy with tolterodine

Exclusion criteria

  • Patients with any contraindication to fesoterodine usage, e.g., urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the drug or its ingredients.
  • Patients with significant hepatic and renal disease or other significant unstable diseases.
  • OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

Treatment and study plan

fesoterodine fumarate

Drug

12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.

Primary outcomes

  1. Mean Number of Micturition Episodes Per 24 Hours

    Time frame: Baseline and Week 12

    The mean number of micturitions per 24 hours is calculated as the total number of micturitions divided by the total number of diary days collected at that visit.

  2. Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours

    Time frame: Baseline and Week 12

    The mean number of UUI episodes per 24 hours is calculated as the total number of micturitions with Bladder Sensation Scale (BSS) = 5 divided by the total number of diary days collected at that visit. BSS: 5 point scale measuring need to urinate from 1=no urgency to 5=unable to hold; leak urine.

  3. Mean Number of Urgency Episodes Per 24 Hours

    Time frame: Baseline and Week 12

    The mean number of urgency episodes per 24 hours is calculated as the total number of micturitions with Bladder Sensation Scale (BSS) >= 3 divided by the total number of diary days collected at that visit. BSS: 5 point scale measuring need to urinate from 1=no urgency to 5=unable to hold; leak urine.

  4. Number of Participants Reporting Satisfaction With Current Overactive Bladder (OAB) Treatment

    Time frame: Week 12

    Number of Participants who responded satisfied = (very satisfied or somewhat satisfied) and dissatisfied = (somewhat dissatisfied or very dissatisfied) to the treatment satisfaction question.

Secondary outcomes

  1. Nocturnal Micturitions Per 24 Hours

    Time frame: Baseline and Week 12

    Nocturnal micturitions (synonymous with the term "nighttime micturitions") were those recorded in the bedtime section of the bladder diary.

  2. Severe Urgency Episodes Per 24 Hours

    Time frame: Baseline and Week 12

    Severe urgency episodes defined as Urinary Sensation Scale (USS) rating ≥4. Subjects rated the feeling of urgency associated with each micturition episode using USS provided in the bladder diary. Scale ranges from 1=no feeling of urgency to 5=unable to hold; leak urine; decrease indicates an improvement with respect to urgency symptoms.

  3. Mean Rating on the Urinary Sensation Scale

    Time frame: Baseline and Week 12

    The mean rating was calculated as the sum of rating scores on the Urinary Sensation Scale divided by the total number of micturitions with non-missing rating at that visit. The scale ranges from 1 "no feeling of urgency" to 5 "unable to hold; leak urine."

  4. Patient Perception of Bladder Condition (PPBC) Score

    Time frame: Baseline and Week 12

    The PPBC score ranges from 1 "no problems at all" to 6 "many severe problems."

  5. Patient Perception of Bladder Condition (PPBC) Score at Week 12 Relative to Baseline (Categorical Change)

    Time frame: Baseline and Week 12

    Improvement: negative score change; No change: score change=0; Deterioration: positive score change

  6. Urgency Perception Scale (UPS)

    Time frame: Baseline and Week 12

    UPS scores range from 0 ("I am usually not able to hold urine") to 2 ("I am usually able to finish what I am doing before going to the toilet [without leaking]").

  7. Urgency Perception Scale (UPS) at Week 12 Relative to Baseline (Categorical Change)

    Time frame: Baseline and Week 12

    Improvement: positive score change; No improvement: zero or negative score change

  8. Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Concern Domain

    Time frame: Baseline and Week 12

    Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.

  9. Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Coping Domain

    Time frame: Baseline and Week 12

    Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.

  10. Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Sleep Domain

    Time frame: Baseline and Week 12

    Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.

  11. Overactive Bladder Questionnaire (OAB-q) - Health Related Quality of Life (HRQL) Social Interaction Domain

    Time frame: Baseline and Week 12

    Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.

  12. Overactive Bladder Questionnaire (OAB-q) - Total Health Related Quality of Life (HRQL) Scale

    Time frame: Baseline and Week 12

    Each item rated by subject on a Likert scale 1 (most favorable) to 6 (least favorable). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent more favorable outcome.

  13. Overactive Bladder Questionnaire (OAB-q) - Symptom Bother Scale

    Time frame: Baseline and Week 12

    Each item rated by subject on a Likert scale 1 (least symptom bother) to 6 (most symptom bother). Raw scores were transformed to a score from 0 to 100. Once transformed, higher scores represent less favorable outcome.

  14. "Satisfaction With OAB Control" Module of Overactive Bladder (OAB) Treatment Satisfaction Questionnaire (TSQ) (OAB-S)

    Time frame: Week 12

    Module coded on scale (1-very satisfied to 5-very dissatisfied). Coding reversed algorithmically & results transformed: total score range 0-100. Higher final response value associated with better satisfaction. Satisfied on TSQ = very or somewhat satisfied; Not satisfied on TSQ =very or somewhat dissatisfied or neither dissatisfied nor satisfied.

  15. Sum Rating on the Urinary Sensation Scale

    Time frame: Baseline and Week 12

    The sum rating per 24 hours was calculated as the mean rating score on the Urinary Sensation Scale multiplied by the mean number of micturitions per 24 hours at that visit. The scale ranges from 1 "no feeling of urgency" to 5 "unable to hold; leak urine."

  16. Treated Subjects Reporting Satisfaction With Their Current OAB Treatment (Supportive Analysis)

    Time frame: Week 12

    Number of participants who responded satisfied = (very satisfied or somewhat satisfied) or dissatisfied = (somewhat dissatisfied or very dissatisfied) to the treatment satisfaction question at Week 12 in the safety set.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A 12-Week, Multicenter, Open-Label, Single-Arm Study To Evaluate The Effects Of Fesoterodine On Treatment Satisfaction And Symptom Relief In Overactive Bladder Patients.

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Jan 22, 2007
Registry last updated
Dec 5, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.